Ginkgo Bioworks Holdings, Inc. (DNA) 주식 분석

회사 개요

Ginkgo Bioworks Holdings, Inc. operates as a specialized developer of cell engineering platforms within the United States, serving the broader healthcare sector through its biotechnology industry classification. The firm executes its operational strategy via two distinct segments, specifically Cell Engineering and Biosecurity, offering comprehensive research and development solutions alongside essential cell engineering tools. Currently, the company maintains a market capitalization of $398.17M and employs a workforce of 485 individuals to support its technological infrastructure. Its annual revenue for the trailing twelve months stands at $170.16M, figures that position the entity as a mid-cap player with significant specialized capabilities rather than a dominant market leader, indicating a scale that relies heavily on platform adoption and strategic partnerships to achieve financial stability in the competitive biotechnology landscape.

재무 건전성

The company reported a trailing twelve-month revenue of $170.16M, yet this generated a net income of $-312,763,008, revealing a cost structure where expenses substantially exceed operating revenues. Additionally, the EBITDA for the same period was recorded at $-267,822,000, further highlighting the operational burn rate inherent in its development phase. Free cash flow for the trailing twelve months amounted to $-72,883,000, which signifies a lack of internal cash generation and a reliance on external capital markets or existing cash reserves to fund ongoing activities. Gross margin stands at 72.4%, suggesting that the company retains a substantial portion of revenue from its core sales, while the operating margin of -209.7% and profit margin of -183.8% indicate severe operational inefficiencies or heavy investment costs relative to current sales levels. On the balance sheet, the company holds $422.62M in cash against total debt of $439.88M, resulting in a debt-to-equity ratio of 86.49, which reflects a highly leveraged position where liabilities slightly outweigh liquid assets. The current ratio is reported at 4.92, implying that the firm possesses ample short-term assets to cover its current liabilities, thereby mitigating immediate liquidity risks despite the long-term debt burden. Return on equity is -51.1% and return on assets is -15.4%, metrics that collectively demonstrate that management is currently destroying shareholder value and failing to generate positive returns on the capital employed in the business.

밸류에이션 평가

The trailing P/E ratio is listed as N/A due to the negative net income, while the forward P/E stands at -1.77, implying that the market is pricing in a trajectory of continued earnings losses or a significant restructuring of profitability expectations. The price-to-book ratio is 0.74, indicating that the market values the company at a discount to its book value, which may reflect skepticism regarding the quality of its intangible assets or future revenue potential. Alternative valuation metrics such as the price-to-sales ratio of 2.34 and an EV/EBITDA of -1.46 suggest that investors are valuing the firm primarily on its sales growth prospects rather than current earnings power. The stock has traded within a 52-week range between a high of $17.58 and a low of $5.37, meaning the current price sits at a level that reflects significant volatility and potential downside risk relative to the recent peak performance. With a beta of 1.57, the stock exhibits price volatility that is substantially higher than the broader market, suggesting that Ginkgo Bioworks Holdings, Inc. is highly sensitive to general market fluctuations and investor sentiment shifts within the biotechnology sector.

Growth & Income

Revenue growth year-over-year has contracted by -23.8%, while earnings growth is N/A due to the company's persistent losses, indicating that the business is shrinking in terms of top-line revenue and failing to improve profitability simultaneously. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy of reinvesting any available earnings or raising new capital to fund growth initiatives rather than returning value directly to shareholders through cash distributions. This non-dividend status aligns with the typical lifecycle of a growth-stage biotechnology firm that prioritizes research and development expenditures over shareholder payouts. The overall growth and income profile for Ginkgo Bioworks Holdings, Inc. is characterized by declining revenue, negative cash generation, and a complete absence of dividend income, painting a picture of a firm in a challenging financial transition period that depends entirely on external funding to sustain operations.